Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis

Tocilizumab for Fulminant Programmed Death 1 Inhibitor–Associated Myocarditis

(2020) Hanping Wang et al.   Journal of Thoracic Oncology

Evolving insights into the mechanisms of toxicity associated with immune checkpoint inhibitor therapy

(2020) Brendan L. Mangan et al.   BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

Major Adverse Cardiovascular Events and the Timing and Dose of Corticosteroids in Immune Checkpoint Inhibitor–Associated Myocarditis

(2020) Lili Zhang et al.   CIRCULATION

Cardiovascular Toxicity Related to Cancer Treatment: A Pragmatic Approach to the American and European Cardio‐Oncology Guidelines

(2020) Joachim Alexandre et al.   Journal of the American Heart Association

Cardiovascular toxicities associated with immune checkpoint inhibitors

(2019) Jiun-Ruey Hu et al.   CARDIOVASCULAR RESEARCH

Myocarditis in the Setting of Cancer Therapeutics

(2019) Marc P. Bonaca et al.   CIRCULATION

Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy

(2019) Khashayar Esfahani et al.   NEW ENGLAND JOURNAL OF MEDICINE

Abatacept for Severe Immune Checkpoint Inhibitor–Associated Myocarditis

(2019) Joe-Elie Salem et al.   NEW ENGLAND JOURNAL OF MEDICINE

Acute Coronary Syndrome With Immune Checkpoint Inhibitors: A Proof-of-Concept Case and Pharmacovigilance Analysis of a Life-Threatening Adverse Event

(2019) Jennifer Cautela et al.   CANADIAN JOURNAL OF CARDIOLOGY

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline

(2018) Julie R. Brahmer et al.   JOURNAL OF CLINICAL ONCOLOGY

Autoimmune Myocarditis Caused by Immune Checkpoint Inhibitors Treated With Antithymocyte Globulin

(2018) Varun Jain et al.   JOURNAL OF IMMUNOTHERAPY

Myocarditis in Patients Treated With Immune Checkpoint Inhibitors

(2018) Syed S. Mahmood et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Increased reporting of fatal immune checkpoint inhibitor-associated myocarditis

(2018) Javid J Moslehi et al.   LANCET

Cancer immunotherapy using checkpoint blockade

(2018) Antoni Ribas et al.   SCIENCE

Immune checkpoint inhibitors and cardiovascular toxicity

(2018) Alexander R Lyon et al.   LANCET ONCOLOGY

Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors

(2018) Daniel Y. Wang et al.   JAMA Oncology

Cardiovascular Magnetic Resonance in Nonischemic Myocardial Inflammation

(2018) Vanessa M. Ferreira et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study

(2018) Joe-Elie Salem et al.   LANCET ONCOLOGY

Potential of Oncocardiology

(2017) Jennifer Cautela et al.   JAMA Cardiology

Fulminant Myocarditis with Combination Immune Checkpoint Blockade

(2016) Douglas B. Johnson et al.   NEW ENGLAND JOURNAL OF MEDICINE

Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper

(2015) S. Champiat et al.   ANNALS OF ONCOLOGY

PD-1 is a novel regulator of human B-cell activation

(2012) Marie-Laure Thibult et al.   INTERNATIONAL IMMUNOLOGY

Myocarditis associated with infliximab

(2010) Eoin Slattery et al.   INFLAMMATORY BOWEL DISEASES